Breaking News, Financial News

Financial Report: Charles River Laboratories 4Q

Preclinical Services (PCS) segment revenue was $158.6 million (-8%) due to slower market demand and the negative impact of foreign exchange.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories 4Q Revenues: $311.4 million (-2%)      4Q Loss: $661.9 million (earnings were $36.9 million in 4Q08)    FY Revenues: $1.3 billion (+9%) FY Loss: $521.8 million (earnings were $154.4 million FY08) Comments: Preclinical Services (PCS) segment revenue was $158.6 million (-8%) due to slower market demand and the negative impact of foreign exchange. For the year PCS revenue was $683.6 million (+5%). Research Models and Services (RMS) segment revenue was $1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters